Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ATI-2173 in Healthy Asian and Non-Asian Subjects
NCT05298332Phase 1Terminated
- Sponsor
- Antios Therapeutics
- Start
- Mar 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ATI-2173 in Chronic Hepatitis B (CHB) (3 cohorts), sponsored by Antios Therapeutics. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 8 more. Started Mar 2022; status: terminated.
02
Drugs
ATI-2173
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05298332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298332.